|
1
|
Yang C, Liu HZ, Fu ZX and Lu WD:
Oxaliplatin long-circulating liposomes improved therapeutic index
of colorectal carcinoma. BMC Biotechnol. 11:212011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nobili S, Checcacci D, Filippelli F, Del
Buono S, Mazzocchi V, Mazzei T and Mini E: Bimonthly chemotherapy
with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic
acid in patients with metastatic colorectal cancer pretreated with
irinotecan- or oxaliplatin-based chemotherapy. J Chemother.
20:622–631. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen AY and Chen YC: A review of the
dietary flavonoid, kaempferol on human health and cancer
chemoprevention. Food Chem. 138:2099–2107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Majumdar D, Jung KH, Zhang H, Nannapaneni
S, Wang X, Amin AR, Chen Z, Chen ZG and Shin DM: Luteolin
nanoparticle in chemoprevention: In vitro and in vivo anticancer
activity. Cancer Prev Res (Phila). 7:65–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sporn MB, Dunlop NM, Newton DL and Smith
JM: Prevention of chemical carcinogenesis by vitamin A and its
synthetic analogs (retinoids). Fed Proc. 35:pp. 1332–1338. 1976;
PubMed/NCBI
|
|
6
|
Madhunapantula SV and Robertson GP:
Chemoprevention of melanoma. Adv Pharmacol. 65:361–398. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mann CD, Neal CP, Garcea G, Manson MM,
Dennison AR and Berry DP: Phytochemicals as potential
chemopreventive and chemotherapeutic agents in
hepatocarcinogenesis. Eur J Cancer Prev. 18:13–25. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khor TO, Yu S and Kong AN: Dietary cancer
chemopreventive agents-targeting inflammation and Nrf2 signaling
pathway. Planta Med. 74:1540–1547. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kaur M, Singh RP, Gu M, Agarwal R and
Agarwal C: Grape seed extract inhibits in vitro and in vivo growth
of human colorectal carcinoma cells. Clin Cancer Res. 12:6194–6202.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaur M, Velmurugan B, Tyagi A, Agarwal C,
Singh RP and Agarwal R: Silibinin suppresses growth of human
colorectal carcinoma SW480 cells in culture and xenograft through
down-regulation of beta-catenin-dependent signaling. Neoplasia.
12:415–424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Benbrook DM, Guruswamy S, Wang Y, Sun Z,
Mohammed A, Zhang Y, Li Q and Rao CV: Chemoprevention of colon and
small intestinal tumorigenesis in APC(min/+) mice by SHetA2
(NSC721689) without toxicity. Cancer Prev Res (Phila). 6:908–916.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang MY, Wang CJ, Chen NF, Ho WH, Lu FJ
and Tseng TH: Luteolin enhances paclitaxel-induced apoptosis in
human breast cancer MDA-MB-231 cells by blocking STAT3. Chem Biol
Interact. 213:60–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang X, Dai S, Dai J, Xiao Y, Bai Y, Chen
B and Zhou M: Luteolin decreases invasiveness, deactivates STAT3
signaling and reverses interleukin-6 induced epithelial-mesenchymal
transition and matrix metalloproteinase secretion of pancreatic
cancer cells. Onco Targets Ther. 8:2989–3001. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yan M, Liu Z, Yang H, Li C, Chen H, Liu Y,
Zhao M and Zhu Y: Luteolin decreases the UVA-induced autophagy of
human skin fibroblasts by scavenging ROS. Mol Med Rep.
14:1986–1992. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee HZ, Yang WH, Bao BY and Lo PL:
Proteomic analysis reveals ATP-dependent steps and chaperones
involvement in luteolin-induced lung cancer CH27 cell apoptosis.
Eur J Pharmacol. 642:19–27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ong CS, Zhou J, Ong CN and Shen HM:
Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells
via the Akt-GSK-3β-cyclin D1 pathway. Cancer Lett. 298:167–175.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chiu FL and Lin JK: Downregulation of
androgen receptor expression by luteolin causes inhibition of cell
proliferation and induction of apoptosis in human prostate cancer
cells and xenografts. Prostate. 68:61–71. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cai X, Ye T, Liu C, Lu W, Lu M, Zhang J,
Wang M and Cao P: Luteolin induced G2 phase cell cycle arrest and
apoptosis on non-small cell lung cancer cells. Toxicol In Vitro.
25:1385–1391. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Balyan R, Kudugunti SK, Hamad HA, Yousef
MS and Moridani MY: Bioactivation of luteolin by tyrosinase
selectively inhibits glutathione S-transferase. Chem Biol Interact.
240:208–218. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu JF, Ma Y, Wang Y, Du ZY, Shen JK and
Peng HL: Reduction of lipid accumulation in HepG2 cells by luteolin
is associated with activation of AMPK and mitigation of oxidative
stress. Phytother Res. 25:588–596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abdel Hadi L, Di Vito C, Marfia G,
Ferraretto A, Tringali C, Viani P and Riboni L: Sphingosine kinase
2 and ceramide transport as key targets of the natural flavonoid
luteolinto induce apoptosis in colon cancer cells. PLoS One.
10:e01433842015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wölfle U, Esser PR, Simon-Haarhaus B,
Martin SF, Lademann J and Schempp CM: UVB-induced DNA damage,
generation of reactive oxygen species and inflammation are
effectively attenuated by the flavonoid luteolin in vitro and in
vivo. Free Radic Biol Med. 50:1081–1093. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Y, Wang L, Zhao Y, He M, Zhang X, Niu
M and Feng N: Nanostructured lipid carriers versus microemulsions
for delivery of the poorly water-soluble drug luteolin. Int J
Pharm. 476:169–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuan Y, Zhao Y, Xin S, Wu N, Wen J, Li S,
Chen L, Wei Y, Yang H and Lin S: A novel PEGylated
liposome-encapsulated SANT75 suppresses tumor growth through
inhibiting hedgehog signaling pathway. PLoS One. 8:e602662013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fetterly GJ, Grasela TH, Sherman JW, Dul
JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M and
Kane MP: Pharmacokinetic/pharmacodynamic modeling and simulation of
neutropenia during phase I development of liposome-entrapped
paclitaxel. Clin Cancer Res. 14:5856–5863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gabizon A, Catane R, Uziely B, Kaufman B,
Safra T, Cohen R, Martin F, Huang A and Barenholz Y: Prolonged
circulation time and enhanced accumulation in malignant exudates of
doxorubicin encapsulated in polyethylene-glycol coated liposomes.
Cancer Res. 54:987–992. 1994.PubMed/NCBI
|
|
27
|
Guo L, Fan L, Ren J, Pang Z, Ren Y, Li J,
Wen Z, Qian Y, Zhang L and Ma H: Combination of TRAIL and
actinomycin D liposomes enhances antitumor effect in non-small cell
lung cancer. Int J Nanomedicine. 7:1449–1460. 2012.PubMed/NCBI
|
|
28
|
Li LT, Jiang G, Chen Q and Zheng JN: Ki67
is a promising molecular target in the diagnosis of cancer
(Review). Mol Med Rep. 11:1566–1572. 2015.PubMed/NCBI
|
|
29
|
Koudelka S, Turanek Knotigova P, Masek J,
Prochazka L, Lukac R, Miller AD, Neuzil J and Turanek J: Liposomal
delivery systems for anti-cancer analogues of vitamin E. J Control
Release. 207:59–69. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Barenholz Y: Doxil® - the first
FDA-approved nano-drug: Lessons learned. J Control Release.
160:117–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schiffelers RM, Metselaar JM, Fens MH,
Janssen AP, Molema G and Storm G: Liposome-encapsulated
prednisolone phosphate inhibits growth of established tumors in
mice. Neoplasia. 7:118–127. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gabizon A and Martin F: Polyethylene
glycol-coated (pegylated) liposomal doxorubicin. Rationale for use
in solid tumours. Drugs. 4 Suppl 54:S15–S21. 1997. View Article : Google Scholar
|
|
33
|
Harris L, Batist G, Belt R, Rovira D,
Navari R, Azarnia N, Welles L and Winer E; TLC D-99 Study Group, :
Liposome-encapsulated doxorubicin compared with conventional
doxorubicin in a randomized multicenter trial as first-line therapy
of metastatic breast carcinoma. Cancer. 94:25–36. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hioki A, Wakasugi A, Kawano K, Hattori Y
and Maitani Y: Development of an in vitro drug release assay of
PEGylated liposome using bovine serum albumin and high temperature.
Biol Pharm Bull. 33:1466–1470. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Deshpande PP, Biswas S and Torchilin VP:
Current trends in the use of liposomes for tumor targeting.
Nanomedicine (Lond). 8:1509–1528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Haley B and Frenkel E: Nanoparticles for
drug delivery in cancer treatment. Urol Oncol. 26:57–64. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cukierman E and Khan DR: The benefits and
challenges associated with the use of drug delivery systems in
cancer therapy. Biochem Pharmacol. 80:762–770. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fan Y, Liu J, Wang D, Song X, Hu Y, Zhang
C, Zhao X and Nguyen TL: The preparation optimization and immune
effect of epimedium polysaccharide-propolis flavone liposome.
Carbohydr Polym. 94:24–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhu Y, Wang M, Zhang J, Peng W, Firempong
CK, Deng W, Wang Q, Wang S, Shi F, Yu J, et al: Improved oral
bioavailability of capsaicin via liposomal nanoformulation:
Preparation, in vitro drug release and pharmacokinetics in rats.
Arch Pharm Res. 38:512–521. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pandurangan AK and Esa NM: Luteolin, a
bioflavonoid inhibits colorectal cancer through modulation of
multiple signaling pathways: A review. Asian Pac J Cancer Prev.
15:5501–5508. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang LM, Xie KP, Huo HN, Shang F, Zou W
and Xie MJ: Luteolin inhibits proliferation induced by IGF-1
pathway dependent ERα in human breast cancer MCF-7 cells. Asian Pac
J Cancer Prev. 13:1431–1437. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pratheeshkumar P, Son YO, Budhraja A, Wang
X, Ding S, Wang L, Hitron A, Lee JC, Kim D, Divya SP, et al:
Luteolin inhibits human prostate tumor growth by suppressing
vascular endothelial growth factor receptor 2-mediated
angiogenesis. PLoS One. 7:e522792012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Matsumura Y and Maeda H: A new concept for
macromolecular therapeutics in cancer chemotherapy: Mechanism of
tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer Res. 46:6387–6392. 1986.PubMed/NCBI
|
|
44
|
Vasey PA, Kaye SB, Morrison R, Twelves C,
Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T,
et al: Phase I clinical and pharmacokinetic study of PK1
[N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First
member of a new class of chemotherapeutic agents-drug-polymer
conjugates. Cancer research campaign phase I/II committee. Clin
Cancer Res. 5:83–94. 1999.PubMed/NCBI
|
